Gibson Dunn Advises Ultragenyx on $400 Million Sale of a Portion of Future North American Royalties on Crysvita® (burosumab)
Firm News | November 5, 2025
Gibson Dunn is advising Ultragenyx Pharmaceutical Inc. on its sale of a portion of future North American royalties on Crysvita® (burosumab) for $400 million.
Gibson Dunn regularly advises life sciences companies on complex royalty monetization and strategic transactions in the biopharmaceutical sector.
The Gibson Dunn corporate team is led by Ryan Murr and Karen Spindler and includes George Hang. Pamela Lawrence Endreny and Ryan Rott are advising on tax aspects.